High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.

CONCLUSIONS: High baseline tumor AURKA and AURKB expression identified MIBC patients with inferior RFS and OS despite the use of NAC and may identify patients who should be prioritized for clinical trial enrollment rather than standard cisplatin-based chemotherapy.
PMID: 31597600 [PubMed - as supplied by publisher]

Source: Urologic Oncology - October 5, 2019 Category: Urology & Nephrology Authors: Burgess EF, Livasy C, Trufan S, Hartman A, Guerreri R, Naso C, Clark PE, Grigg C, Symanowski J, Raghavan D Tags: Urol Oncol Source Type: research